{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-25-016864","form_type":"8-K","ticker":"MDCX","cik":"0001997296","company_name":"Medicus Pharma Ltd.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.246895+00:00","generated_at":"2026-05-16T19:57:15.480436+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Medicus Pharma Q3 net loss $16M, pipeline advances with SkinJect and Teverelix","bullets":["Net loss $16.0M in Q3 2025 vs $2.3M in Q3 2024; R&D $1.7M, G&A $5.0M.","Cash $8.7M at Sep 30, 2025, up from $5.3M; raised $10.4M from financings and warrant exercises.","Phase 2 SKNJCT-003 >75% enrolled; FDA Type C meeting supports 505(b)(2) pathway for D-MNA (BCC).","Completed Antev acquisition (Teverelix, GnRH antagonist) in August 2025; UK approvals for SKNJCT-003 expansion.","Strategic collaboration with Gorlin Syndrome Alliance for expanded access to SkinJect under FDA IND."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-25-016864","json":"https://secwatch.observer/filing/0001062993-25-016864.json","markdown":"https://secwatch.observer/filing/0001062993-25-016864.md","text":"https://secwatch.observer/filing/0001062993-25-016864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325016864/0001062993-25-016864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325016864/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:57:15.480436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}